STING1 and cancer: Although the STING agonist adjuvant has drawn great interest in vaccine development against infectious pathogens and cancers,[31] the utility of cyclic dinucleotides and assessment of their adjuvancy effect to alternative adjuvants have been challenging owing to the poor intracellular delivery efficiency of the compound.